Amgen Names Robert A. Bradway Chairman of the Board Of Directors

       Amgen Names Robert A. Bradway Chairman of the Board Of Directors

Current Director Vance D. Coffman Named Lead Independent Director

PR Newswire

THOUSAND OAKS, Calif., Dec. 13, 2012

THOUSAND OAKS, Calif., Dec. 13, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN)
today announced appointments to its Board of Directors. Robert A. Bradway,
chief executive officer, has been appointed chairman of the Board, and Vance
D. Coffman, an Amgen director since 2007, has been appointed lead independent
director, both effective on Jan. 1, 2013. As previously announced, Kevin W.
Sharer is retiring from the Board, effective Dec. 31, 2012.

"On behalf of the Board and all of Amgen, we look forward to Vance Coffman's
continued contributions as the new lead independent director," said Bradway,
"and we thank Kevin Sharer for his 20 years of dedicated service and his
contributions to the company and the patients we serve."

Robert A. Bradway

Mr. Bradway, 49, has served as Amgen's Chief Executive Officer since May 2012
and was appointed to the Amgen Board of Directors in October 2011. He joined
the company in 2006 as Vice President, Operations Strategy, and served as
Executive Vice President and Chief Financial Officer from 2007 to 2010. Prior
to joining Amgen, Mr. Bradway was a Managing Director at Morgan Stanley. Mr.
Bradway holds a Bachelor of Arts degree in biology from Amherst College and a
Masters in Business Administration degree from Harvard University. He is a
member of the Board of Directors of Norfolk Southern Corporation.

Vance D. Coffman

Dr. Coffman, 68, has served as a director of the Company since October 2007.
Dr. Coffman served in various executive capacities at Lockheed Martin
Corporation, a high technology aerospace and defense company. He served as
Vice Chairman of the Board and Chief Executive Officer from 1997, as Chairman
of the Board and Chief Executive Officer from 1998 until 2004, and as Chairman
of the Board until 2005. He is a Member of the National Academy of Engineering
and a Fellow in the American Institute of Aeronautics and Astronautics and the
American Astronautical Society. He is also a director of 3M Company and Deere
& Company.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first
companies to realize the new science's promise by bringing safe and effective
medicines from lab, to manufacturing plant, to patient. Amgen therapeutics
have changed the practice of medicine, helping millions of people around the
world in the fight against cancer, kidney disease, rheumatoid arthritis, bone
disease and other serious illnesses. With a deep and broad pipeline of
potential new medicines, Amgen remains committed to advancing science to
dramatically improve people's lives. To learn more about our pioneering
science and our vital medicines, visit www.amgen.com. Follow us on
www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

SOURCE Amgen

Website: http://www.amgen.com
 
Press spacebar to pause and continue. Press esc to stop.